BAYER AG-REG said the U.S. Food and Drug Administration accepted its supplemental New Drug Application for finerenone and granted priority review designation. The application seeks to expand the drug's use to adults with chronic kidney disease (CKD) associated with type 1 diabetes. Finerenone is already approved for CKD associated with type 2 diabetes.

Clinical Data Drives Regulatory Fast-Track